Precision delivery of RAS-inhibiting siRNA to KRAS driven cancer via peptide-based nanoparticles. - Strand MS; Krasnick BA; Pan H; Zhang X; Bi Y; Brooks C; Wetzel C; Sankpal N; Fleming T; Goedegebuure SP; DeNardo DG; Gillanders WE; et al. (Oncotarget, 2019)